Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
How did AMRN's recent EPS compare to expectations?
The most recent EPS for Amarin Corporation PLC is $-0.09, not beating expectations of $0.08.
How did Amarin Corporation PLC AMRN's revenue perform in the last quarter?
Amarin Corporation PLC revenue for the last quarter is $-0.09
What is the revenue estimate for Amarin Corporation PLC?
According to 4 of Wall street analyst, the revenue estimate of Amarin Corporation PLC range from $46.77M to $43.41M
What's the earning quality score for Amarin Corporation PLC?
Amarin Corporation PLC has a earning quality score of B+/52.274643. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Amarin Corporation PLC report earnings?
Amarin Corporation PLC next earnings report is expected in 2026-07-28
What are Amarin Corporation PLC's expected earnings?
Amarin Corporation PLC expected earnings is $44.64M, according to wall-street analysts.
Did Amarin Corporation PLC beat earnings expectations?
Amarin Corporation PLC recent earnings of $45.13M beat expectations.